Comparing mutation frequencies for homologous recombination genes in uterine serous and high-grade serous ovarian carcinomas: A case for homologous recombination deficiency testing in uterine serous carcinoma.

Abstract:

OBJECTIVE:To compare the frequencies of somatic homologous recombination (HR) gene mutations identified in next-generation sequencing (NGS) genomic profiling of uterine serous carcinomas (USCs) and high-grade serous ovarian carcinomas (HGSOCs). METHODS:Data for this analysis was obtained from AACR Project GENIE, a multi-institutional dataset of clinical-grade NGS genomic profiling results for many cancer sites and histologic subtypes, through cBioPortal. Patient/specimen groups used for analysis were USC and HGSOC. 14 HR genes were queried for each group with respect to mutation frequency. For each HR gene, the difference in mutation frequency between the two groups was evaluated using Fisher's exact test. The threshold for statistical significance was p-value < .05. RESULTS:In the USC group, there were 457 samples from 451 patients. In the HGSOC group, there were 1537 samples from 1515 patients. The most frequently mutated HR gene for USC was BRCA2 (4.84%) and for HGSOC was BRCA1 (9.07%). Mutation frequency was significantly different between USC and HGSOC for BRCA 1 (p < .001) and BRCA2 (p = .0379). For the 12 non-BRCA HR genes, mutation frequency was not significantly different between USC and HGSOC. The rate of patients with at least one HR gene mutation in their profiled tumor was 16.85% for USC and 25.21% of HGSOC. Most USC patients with a somatic HR mutation had only one HR gene mutated. CONCLUSIONS:Somatic HR gene mutations were commonly identified in NGS genomic profiling of USC. Mutation frequencies for non-BRCA HR genes were not significantly different between USC and HGSOC. These data add to the growing rationale for HR deficiency tumor testing and targeting (e.g., with PARP inhibitors) in future clinical trial development for women with USC.

journal_name

Gynecol Oncol

journal_title

Gynecologic oncology

authors

Wallbillich JJ,Morris RT,Ali-Fehmi R

doi

10.1016/j.ygyno.2020.08.012

subject

Has Abstract

pub_date

2020-11-01 00:00:00

pages

381-386

issue

2

eissn

0090-8258

issn

1095-6859

pii

S0090-8258(20)33813-0

journal_volume

159

pub_type

杂志文章
  • Overall survival results of AGO-OVAR16: A phase 3 study of maintenance pazopanib versus placebo in women who have not progressed after first-line chemotherapy for advanced ovarian cancer.

    abstract:OBJECTIVE:The AGO-OVAR16 study was designed to test the efficacy, safety, and tolerability of pazopanib maintenance after first-line chemotherapy in patients with newly diagnosed advanced ovarian cancer (AOC). METHODS:Nine hundred and forty patients with histologically confirmed AOC, International Federation of Gyneco...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1016/j.ygyno.2019.08.024

    authors: Vergote I,du Bois A,Floquet A,Rau J,Kim JW,Del Campo JM,Friedlander M,Pignata S,Fujiwara K,Colombo N,Mirza MR,Monk BJ,Tsibulak I,Calvert PM,Herzog TJ,Hanker LC,Meunier J,Lee JY,Bologna A,Carrasco-Alfonso MJ,Harter

    更新日期:2019-11-01 00:00:00

  • Assessment and management of diarrhea following VEGF receptor TKI treatment in patients with ovarian cancer.

    abstract::Angiogenesis is a proven clinical target for the treatment of advanced epithelial ovarian cancer. Vascular endothelial growth factor receptor tyrosine kinase inhibitors (VEGFR-TKIs) offer patients potential new treatment regimens as they can be given as monotherapy, in combination with poly(ADP-ribose) polymerase (PAR...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章,评审

    doi:10.1016/j.ygyno.2018.03.058

    authors: Liu J,Nicum S,Reichardt P,Croitoru K,Illek B,Schmidinger M,Rogers C,Whalen C,Jayson GC

    更新日期:2018-07-01 00:00:00

  • The significance of peritoneal cytology in patients with carcinoma of the cervix.

    abstract::Between 1972 and 1977, 141 patients with benign gynecologic disease and 149 patients with carcinoma of the cervix were evaluated with peritoneal fluid cytology at time of celiotomy. There was no positive cytology (malignant cells) in the benign disease group. The overall incidence of positive peritoneal cytology in th...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/0090-8258(84)90069-6

    authors: Abu-Ghazaleh S,Johnston W,Creasman WT

    更新日期:1984-02-01 00:00:00

  • Stage IV ovarian cancer: disease site-specific rationale for postoperative treatment.

    abstract:OBJECTIVES:We aimed to define the site-specific patterns of treatment failure in stage IV ovarian cancer. METHODS:Data from all consecutive Mayo Clinic patients with stage IV epithelial ovarian cancer, from 1994 through 2003, were collected and analyzed. Statistical analyses included the chi(2) test and Kaplan-Meier c...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2008.09.010

    authors: Aletti GD,Podratz KC,Cliby WA,Gostout BS

    更新日期:2009-01-01 00:00:00

  • Risk assessment model for overall survival in patients with locally advanced cervical cancer treated with definitive concurrent chemoradiotherapy.

    abstract:OBJECTIVE:To develop a nomogram for predicting the probability of 5year survival after definitive concurrent chemoradiotherapy (CCRT) in locally advanced cervical cancer (LACC). METHODS:Between 1998 and 2008, 209 patients with LACC were treated with definitive CCRT. Multivariate analysis using Cox proportional hazards...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2012.09.033

    authors: Shim SH,Lee SW,Park JY,Kim YS,Kim DY,Kim JH,Kim YM,Kim YT,Nam JH

    更新日期:2013-01-01 00:00:00

  • Metastatic dermatofibrosarcoma protuberans of the vulva.

    abstract::Dermatofibrosarcoma protuberans (DFSP) of the vulva is a rare, low- to intermediate-grade sarcoma of dermal origin. This case report represents the 13th reported patient with vulvar DFSP and the first reported patient with metastatic vulvar DFSP. Although metastasis is rare, the possibility remains that the frequent r...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1006/gyno.1998.5173

    authors: Soergel TM,Doering DL,O'connor D

    更新日期:1998-11-01 00:00:00

  • Surgical treatment of diaphragm disease correlates with improved survival in optimally debulked advanced stage ovarian cancer.

    abstract:BACKGROUND:Diaphragm involvement by ovarian cancer is often considered to be a major obstacle to successful cytoreductive surgery. Lack of evidence of survival benefit, concerns over safety and lack of experience are common justifications for this belief. In this study, we sought to evaluate the therapeutic value of di...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2005.08.027

    authors: Aletti GD,Dowdy SC,Podratz KC,Cliby WA

    更新日期:2006-02-01 00:00:00

  • Development and characterization of an IL-4-secreting human ovarian carcinoma cell line.

    abstract::Human ovarian carcinoma cell lines were genetically engineered to secrete the cytokine interleukin-4 (IL-4) by retroviral-mediated gene transduction. These cells were transduced with the LXSN retroviral vector containing the human IL-4 gene and the neomycin resistance selection marker. Numerous IL-4-secreting clones w...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1006/gyno.1995.1216

    authors: Santin AD,Ioli GR,Hiserodt JC,Rose GS,Graf MR,Tocco LM,Lander JK,Eck LM,Burger RA,DiSaia PJ

    更新日期:1995-08-01 00:00:00

  • Role of hysterectomy in management of gestational trophoblastic disease.

    abstract:OBJECTIVE:To evaluate incidence, indications, and outcome of hysterectomy in women presenting with gestational trophoblastic disease. METHODS:A prospective observational study using a standardized protocol for registration, assessment, and treatment of gestational trophoblastic disease. A total of 5976 consecutive new...

    journal_title:Gynecologic oncology

    pub_type: 临床试验,杂志文章

    doi:10.1006/gyno.2002.6814

    authors: Pisal N,North C,Tidy J,Hancock B

    更新日期:2002-11-01 00:00:00

  • Voiding recovery after radical parametrectomy in cervical cancer patients: An international prospective multicentre trial - SENTIX.

    abstract:OBJECTIVE:Voiding dysfunctions represent a leading morbidity after radical hysterectomy performed in patients with early-stage cervical cancer. The aim of this study was to perform ad hoc analysis of factors influencing voiding recovery in SENTIX (SENTinel lymph node biopsy in cervIX cancer) trial. METHODS:The SENTIX ...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2020.12.018

    authors: Zapardiel I,Kocian R,Köhler C,Klat J,Germanova A,Jacob A,Bajsova S,Böhmer G,Lay L,Gil-Ibañez B,Havelka P,Kipp B,Szewczyk G,Toth R,Staringer JC,De Santiago J,Coronado PJ,Poka R,Laky R,Luyckx M,Fastrez M,Dusek L,

    更新日期:2021-01-05 00:00:00

  • CO2 laser therapy for cervical intraepithelial neoplasia.

    abstract::One hundred and fifty-six patients with cervical intraepithelial neoplasia (CIN) were treated with CO2 laser and followed for 2 1/2 to 6 years. There were 19 recurrences, of which 14 occurred in patients treated with a power density of less than 1000 W/cm2 to a depth of 6 mm. All of the recurrences were subjected to a...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/0090-8258(85)90006-x

    authors: Caglar H,Ayhan A,Hreshchyshyn MM

    更新日期:1985-09-01 00:00:00

  • 53BP1 expression in sporadic and inherited ovarian carcinoma: Relationship to genetic status and clinical outcomes.

    abstract:OBJECTIVES:53BP1, a critical mediator of the DNA damage response, functions by regulating the balance between homologous recombination (HR) and the more error-prone non-homologous endjoining (NHEJ). Deletion of 53BP1 in brca1 (but not brca2) null cells partially restores HR and reverses sensitivity to poly-ADP-ribose p...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2012.12.007

    authors: Pennington KP,Wickramanayake A,Norquist BM,Pennil CC,Garcia RL,Agnew KJ,Taniguchi T,Welcsh P,Swisher EM

    更新日期:2013-03-01 00:00:00

  • Should the presence of lymphvascular space involvement be used to assign patients to adjuvant therapy following hysterectomy for unstaged endometrial cancer?

    abstract::Objective. Thegoal of this study was to determine the influence of LVSI (lymphvascular space involvement) on the risk of lymph node metastases from endometrial cancer.Methods. All patients with surgically staged endometrial cancer from 1998 to 2000 were identified from divisional databases. The influence of LVSI on th...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1006/gyno.2002.6825

    authors: Cohn DE,Horowitz NS,Mutch DG,Kim SM,Manolitsas T,Fowler JM

    更新日期:2002-12-01 00:00:00

  • Ovarian preservation during the surgical treatment of early stage endometrial cancer: a nation-wide study conducted by the Korean Gynecologic Oncology Group.

    abstract:OBJECTIVES:The objective of this study was to determine whether ovarian preservation is feasible in younger endometrial cancer patients. METHODS:Endometrial cancer patients who underwent ovary-saving surgery were recruited from the tumor registries of 14 tertiary hospitals under the influence of the Korean Gynecologic...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2009.06.041

    authors: Lee TS,Kim JW,Kim TJ,Cho CH,Ryu SY,Ryu HS,Kim BG,Lee KH,Kim YM,Kang SB,Korean Gynecologic Oncology Group.

    更新日期:2009-10-01 00:00:00

  • Vascular endothelial growth factor (VEGF) up-regulates epidermal growth factor receptor (EGF-R) in cervical cancer in vitro: this action is mediated through HPV-E6 in HPV-positive cancers.

    abstract:OBJECTIVES:Epidermal Growth Factor Receptor (EGF-R) up-regulation in cervical cancer cells leads to an increase in cell proliferative Insulin-like Growth Factor II (IGF-II) and Vascular Endothelial Growth Factor (VEGF) and a decrease of the anti-proliferative IGF-binding protein-3 (IGF-BP3). The objectives for this stu...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2004.12.011

    authors: Mathur RS,Mathur SP

    更新日期:2005-04-01 00:00:00

  • Prognostic implication of endometriosis in clear cell carcinoma of the ovary.

    abstract:OBJECTIVE:The aim of this study is to investigate whether the presence of endometriosis is a prognostic factor in patients diagnosed with clear cell carcinoma (CCC) of the ovary. METHODS:Retrospective chart review was performed to all patients diagnosed with CCC and endometriosis between 1975 and 2002. All pathology r...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2008.05.025

    authors: Orezzoli JP,Russell AH,Oliva E,Del Carmen MG,Eichhorn J,Fuller AF

    更新日期:2008-09-01 00:00:00

  • Standing on the shoulders of giants: Mentorship advice from leaders in the field.

    abstract::This commentary is presenting opinions and advice on mentorship in the field of gynecologic oncology. Eleven academic gynecologic oncologists from across the country were interviewed and their thoughts about mentorship were recorded with recurring themes and ideas described in this commentary. Trust, respect, and mutu...

    journal_title:Gynecologic oncology

    pub_type: 社论

    doi:10.1016/j.ygyno.2021.01.017

    authors: Boitano TKL,Chi DS,Copeland LJ,Straughn JM Jr

    更新日期:2021-01-27 00:00:00

  • Choriocarcinoma in a term placenta with maternal metastases.

    abstract::Choriocarcinoma of the nonmolar placenta is presumptively a rare entity and is usually associated with widespread maternal metastases at the time of diagnosis. Nonmetastatic disease goes unrecognized and undiagnosed because placental carcinoma can be limited to a few villi, and grossly evident disease is often misinte...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章,评审

    doi:10.1016/0090-8258(92)90264-j

    authors: Christopherson WA,Kanbour A,Szulman AE

    更新日期:1992-08-01 00:00:00

  • Fertility-sparing options for early stage cervical cancer.

    abstract:OBJECTIVE:To review the literature on fertility-sparing options for women with early stage cervical cancer and outline patient selection criteria, operative, oncologic, and pregnancy outcomes. METHODS:The literature was searched using MEDLINE (OVID: 1950 through October 2009) and EMBASE (OVID: 1988 through October 200...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章,评审

    doi:10.1016/j.ygyno.2010.01.039

    authors: Gien LT,Covens A

    更新日期:2010-05-01 00:00:00

  • Are self-collected samples comparable to physician-collected cervical specimens for human papillomavirus DNA testing? A systematic review and meta-analysis.

    abstract:OBJECTIVE:To compare the detection rate of genital human papillomavirus (HPV) infection in self- and physician-obtained samples. DESIGN:Systematic review and meta-analysis. DATA SOURCES:Studies published between 1966 and November 2005 identified through Medline and Embase that compared both sampling methods. MAIN OU...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章,meta分析,评审

    doi:10.1016/j.ygyno.2007.01.023

    authors: Petignat P,Faltin DL,Bruchim I,Tramèr MR,Franco EL,Coutlée F

    更新日期:2007-05-01 00:00:00

  • Evaluating class III antiarrhythmic agents as novel MYC targeting drugs in ovarian cancer.

    abstract:OBJECTIVE:To evaluate the utility of amiodarone and its derivative dronedarone as novel drug repositioning candidates in EOC and to determine the potential pathways targeted by these drugs. METHODS:Drug-predict bioinformatics platform was used to assess the utility of amiodarone as a novel drug-repurposing candidate i...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2018.09.019

    authors: Belur Nagaraj A,Joseph P,Kovalenko O,Wang Q,Xu R,DiFeo A

    更新日期:2018-12-01 00:00:00

  • Retroperitoneal leiomyosarcoma: eight cases and a literature review.

    abstract::Leiomyosarcoma, a rare malignancy of smooth muscle, may arise from the retroperitoneum and present with the same vague symptoms as a malignancy of the pelvic organs. The purpose of this paper is to review eight cases of retroperitoneal leiomyosarcoma and to illustrate the presenting symptoms, prognostic indicators, an...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章,评审

    doi:10.1006/gyno.1995.9967

    authors: Todd CS,Michael H,Sutton G

    更新日期:1995-12-01 00:00:00

  • Bilateral ultrastaging of sentinel lymph node in cervical cancer: Lowering the false-negative rate and improving the detection of micrometastasis.

    abstract:OBJECTIVE:To evaluate the sensitivity of sentinel node (SN) ultrastaging and to define parameters that may reduce the overall false-negative rate in women with early-stage cervical cancer. METHODS:We analyzed data from a large retrospective multicenter cohort group with FIGO stages IA-IIB cervical cancer in whom at le...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章,多中心研究

    doi:10.1016/j.ygyno.2012.08.035

    authors: Cibula D,Abu-Rustum NR,Dusek L,Slama J,Zikán M,Zaal A,Sevcik L,Kenter G,Querleu D,Jach R,Bats AS,Dyduch G,Graf P,Klat J,Meijer CJ,Mery E,Verheijen R,Zweemer RP

    更新日期:2012-12-01 00:00:00

  • Urinary gonadotropin fragment, a new tumor marker. II. Differentiating a benign from a malignant pelvic mass.

    abstract::We examined the efficacy of CA125 and urinary gonadotropin fragment (UGF) measurements for differentiating benign from malignant pelvic masses. CA125, at a cutoff of greater than or equal to 35 U/ml, detected 82% (n = 71) of ovarian malignancies, but also falsely detected 14% of (n = 332) patients with benign pelvic m...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/0090-8258(90)90149-f

    authors: Cole LA,Nam JH,Chambers JT,Schwartz PE

    更新日期:1990-03-01 00:00:00

  • The efficacy of complex decongestive physiotherapy (CDP) and predictive factors of response to CDP in lower limb lymphedema (LLL) after pelvic cancer treatment.

    abstract:OBJECTIVE:The aim of this study was to estimate the efficacy of an intensive CDP program, as well as to identify the predictors associated with lymphedema severity and response to CDP in lower limb lymphedema (LLL) after pelvic cancer therapy. METHODS:We performed a retrospective review of post-pelvic cancer LLL patie...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2012.03.017

    authors: Liao SF,Li SH,Huang HY

    更新日期:2012-06-01 00:00:00

  • Prognostic significance of differential expression of angiogenic genes in women with high-grade serous ovarian carcinoma.

    abstract:OBJECTIVES:To identify angiogenic biomarkers associated with tumor angiogenesis and clinical outcome in high-grade serous ovarian cancer (HGSC). METHODS:51 HGSC samples were analyzed using Affymetrix HG-U133A microarray. Microvessel density (MVD) counts were determined using CD31 and CD105. Associations between mRNA e...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2015.08.001

    authors: Siamakpour-Reihani S,Owzar K,Jiang C,Turner T,Deng Y,Bean SM,Horton JK,Berchuck A,Marks JR,Dewhirst MW,Alvarez Secord A

    更新日期:2015-10-01 00:00:00

  • Stage II endometrioid adenocarcinoma of the endometrium: clinical implications of cervical stromal invasion.

    abstract:OBJECTIVES:Endometrioid adenocarcinoma of the endometrium (EEC) is the most common histologic type of endometrial cancer, with stage being the most critical prognostic factor. Cervical involvement (CI), divided into IIA (epithelial involvement) and IIB (stromal invasion), is overall associated with decreased survival (...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2009.03.007

    authors: Orezzoli JP,Sioletic S,Olawaiye A,Oliva E,del Carmen MG

    更新日期:2009-06-01 00:00:00

  • Bcl-X(L) is functionally non-equivalent for the regulation of growth and survival in human ovarian cancer cells.

    abstract:OBJECTIVE:To investigate the role of Bcl-X(L) on the growth and survival of human ovarian carcinoma cells. METHODS:In this study, we enforced down-regulation of Bcl-X(L) by RNA interference in ovarian carcinoma cell lines CaOV3, SKOV3ip1 and OVCAR3 cell lines expressing various levels of Bcl-X(L). We also established ...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2005.08.028

    authors: Dodier P,Piché A

    更新日期:2006-02-01 00:00:00

  • First-line treatment regimens and the role of consolidation therapy in advanced ovarian cancer.

    abstract::Current first-line management for advanced ovarian cancer consists of cytoreductive surgery followed by chemotherapy, usually with a platinum/taxane combination. Although this approach has been shown to achieve overall response rates of 70-80% in clinical trials, the majority of patients relapse. A number of different...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章,评审

    doi:10.1016/s0090-8258(03)00472-4

    authors: Stuart GC

    更新日期:2003-09-01 00:00:00

  • Stage II endometrial carcinoma: prognostic factors and the results of treatment.

    abstract::Results of treatment and potential prognostic factors in 54 patients with clinical stage II endometrial carcinoma were analyzed. During the period analyzed, three different treatment techniques were used. The highest cure rate (70.6%) was observed in patients treated with simple hysterectomy and bilateral salpingo-oop...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/0090-8258(90)90045-m

    authors: Andersen ES

    更新日期:1990-08-01 00:00:00